cannabidiol (EMD-RX5)
/ Emyria
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 26, 2024
A Phase III study to investigate the effect of EMD-RX5 on symptoms of psychological distress in adults with chronic pain
(ANZCTR)
- P3 | N=300 | Suspended | Sponsor: Emyria Ltd | Recruiting ➔ Suspended
Trial suspension • CNS Disorders • Pain
September 01, 2023
A Phase III study to investigate the effect of EMD-RX5 on symptoms of psychological distress in adults with chronic pain
(ANZCTR)
- P3 | N=300 | Recruiting | Sponsor: Emyria Ltd | Initiation date: Jan 2000 ➔ Jan 2023
Trial initiation date • CNS Disorders • Pain
April 04, 2023
"$ASX:EMD Emyria agrees licensing and commercialisation deal for EMD-RX5 https://t.co/MlrD4dbMH0"
(@otcdynamics)
1 to 3
Of
3
Go to page
1